Description
[ Sequence ]
H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
[ CAS NO. ] 910463-68-2
[ Molecular Formula ] C187H291N45O59
[ Molecular Weight ] 4,113.64
[ Appearance ] White Crystalline Powder
[ Purity ] 99.38%
[ Identification ] Infrared Absorption
[ Loss On Drying ] ≤0.2%
[ Residue On Ignition ] : ≤0.3%
[ Chloride ] ≤0.05%
[ Sulfate ] ≤0.03%
[ Heavy Metals ] ≤0.0015%
[ Application ]
1. Used as both injection-type or oral-type drug.
2. Used for the treatment of obesity.
3. Improve cardiovascular function
4. Treatment of type 2 diabetes in adults
About Semaglutide
Semaglutide(Ozempic) is a glucagon-like peptide-1 analogue for once-weekly subcutaneous treatment of type 2 diabetes.Semaglutide is a pharmaceutical drug which is used for the treatment of type 2 diabetes. Semaglutide has demonstrated the potential to improve the treatment of type 2 diabetes and the positive recommendation from the Advisory Committee marks an important step towards making semaglutide available to adults with type 2 diabetes in the US. Semaglutide(Ozempic), a newly once-weekly glucagon like peptide-1 (GLP-1) receptor agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 diabetes mellitus (T2DM).
In humans semaglutide is chemically similar to glucagon-like peptide-1 (GLP-1).
Semaglutide is a glucagon-like peptide-1 (GLP-1) analog and functions as a GLP-1 agonist.
Furthermore, semaglutide demonstrated a significant, beneficial effect on cardiovascular outcomes and a safety profile similar to that of other GLP-1 receptor agonists.Semaglutide also improves cardiovascular function, reduces the risk of stroke by 39%, and reduces the risk of myocardial infarction by 26%.
